KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

US8623822B2 · kind B2 · utility

Assignee

• Bracco Suisse SA · CH

Inventors

• Christophe Arbogast · Bonneville, FR
• Philippe Bussat · Cognac, FR
• Hong Fan · Princeton Junction, US
• Sudha Khurana · Santa Clara, US
• Karen E. Linder · Kingston, US
• Edmund R. Marinelli · Tucson, US
• Palaniappa Nanjappan · Princeton, US
• Adrian D. Nunn · Lambertville, US
• Radhakrishna K. Pillai · Kendall Park, US
• Sibylle Pochon · Worb, CH
• Kondareddiar Ramalingam
• Ajay Shrivastava · Princeton, US
• Bo Song · Princeton, US
• Rolf E. Swenson · Grayslake, US
• Mathew A. Von Wronski · Moorestown, US
• Feng Yan · Carouge, CH

Key dates

• Filing date: Oct 5, 2010
• Grant date: Jan 7, 2014
• Expiry date: Oct 14, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 μM), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.